IMPORTANT SAFETY INFORMATION & INDICATION
Do not take DHIVY with antidepressant medications known as nonselective monoamine oxidase (MAO) inhibitors because taking these two drugs within 2 weeks of each other can result in high blood pressure. Do not take DHIVY if you have hypersensitivity to any ingredient of DHIVY.
Taking DHIVY may result in falling asleep while engaged in normal activities, even without warning and as late as one year or later after starting DHIVY. Do not drive or operate machinery until you know how DHIVY affects you.
Tell your healthcare provider if you have any heart conditions, especially if you have had a heart attack or irregular heartbeats; if you experience hallucinations or abnormal thoughts and behaviors (such as excessive suspicion, believing things that are not real, confusion, agitation, aggressive behavior, and disorganized thinking); if you have intense urges to gamble, increased sexual urges, other intense urges, and the inability to control those urges; if dyskinesia or abnormal involuntary movements appear or get worse during treatment with DHIVY; if you develop symptoms such as depression, confusion, cheilosis, glossitis, dermatitis, anemia, neuropathy, and/or seizures (which may be a vitamin B6 deficiency); if you have ever had a peptic ulcer or glaucoma; if you have any abnormal lab results; or if you experience depression or suicidal thoughts.
Notify your healthcare provider if you become pregnant or intend to become pregnant during DHIVY therapy or if you intend to breastfeed or are breastfeeding an infant.
Talk to your healthcare provider before you lower the dose or stop taking DHIVY, as this may result in serious side effects. Call your healthcare provider immediately if you develop withdrawal symptoms such as fever, confusion, or severe muscle stiffness.
Take DHIVY as instructed. You may take DHIVY with or without food. If you have difficulty swallowing the tablet due to its size, you may break the tablet along the score lines.
The most common adverse reactions reported with carbidopa/levodopa tablets have included abnormal involuntary movements and nausea.
DHIVY is a combination of carbidopa and levodopa indicated for the treatment of Parkinson’s disease, postencephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication.
You may report side effects to Avion Pharmaceuticals, LLC at 1-888-612-8466 or to the FDA at 1-800-FDA-1088.
Please click here for full Prescribing
Information.
